Skip to main content

Skip to main navigation

The Economic Case for Universal Pharmacare

Costs and benefits of publicly funded drug coverage for all Canadians

About this Publication

The main argument that is typically made against the establishment of universal Pharmacare is economic in nature. This report shows that the economic argument in favour of such a program is loud and clear, regardless of which industrial policy is subsequently considered. Canadians could save between 10% and 42%—up to $10.7 billion—of total drug expenditures.

A universal drug plan providing first-dollar coverage, established alongside a rigorous drug assessment process, would not only ensure greater fairness in accessing medication and improve drug safety, but would also help contain the inflationary costs of drugs, regardless of the industrial policy Canada may choose.

Find Publications

Support Our Work

The CCPA’s bold vision and creative solutions help us imagine better futures for all. Its efforts to build bridges between labour, industry, and civil society and mentor young activists lay the foundation for realizing those provocative futures. I consider my support for the CCPA an investment in a better future for British Columbia.

— Polly Ng, Next Up graduate

Join or Donate

Email Newswire

Stay up to date on new research:
About our newswire service
CCPA National Office | Suite 500, 251 Bank Street, Ottawa ON, K2P 1X3 | Tel: 613-563-1341 | Fax: 613-233-1458 | E-mail: ccpa@policyalternatives.ca
© 2013 Canadian Centre for Policy Alternatives | research • analysis • solutions | Want to use something on this site? View our terms of re(use)
Website Design & Development by Raised Eyebrow Web Studio